Disparities in emergency contraceptive metabolism dictate efficacy
紧急避孕药代谢的差异决定了功效
基本信息
- 批准号:10518960
- 负责人:
- 金额:$ 79.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-20 至 2027-06-30
- 项目状态:未结题
- 来源:
- 关键词:AcetatesAllelesAnimal ModelAnimalsAsthmaBindingBiologicalBlack PopulationsBlack raceBloodBlood specimenBody mass indexCYP3A4 geneCYP3A5 geneCardiovascular DiseasesCell physiologyCharacteristicsCommunicable DiseasesContraceptive AgentsContraceptive AvailabilityContraceptive UsageContraceptive methodsCytochrome P450DataDevelopmentDoseDrug KineticsEconomicsEnrollmentEnzymesEstradiolFailureFollicular FluidFrequenciesGene ExpressionGene FrequencyGenesGeneticGenetic Predisposition to DiseaseGenomicsGenotypeGoalsHalf-LifeHealthHumanHypertensionIndividualInterventionKineticsKnowledgeLeadLiverLuteinizing HormoneMacaca mulattaMalignant NeoplasmsMedicalMetabolismMethodsModelingMonitorObesityOocytesOralOther GeneticsOutcomeOvarianOvarian FollicleOvaryOvulationPersonal SatisfactionPersonsPharmaceutical PreparationsPharmacodynamicsPharmacogenomicsPhenotypePlayPopulationPregnancyPrimatesProcessProgesteronePublishingRaceRegression AnalysisReportingResearchRiskRoleRuptureSamplingSerumSex DiscriminationSiteStimulusStudy SubjectTestingTherapeuticTimeTransvaginal UltrasoundUnited StatesVariantWomanWorkagedbaseclinically relevantcontraceptive efficacydesigndrug efficacydrug metabolismemergency contraceptionenzyme activityexperiencegenetic variantgranulosa cellhealth care availabilityhealth disparityhealth inequalitieshuman subjectinhibitorintraovariannonhuman primatenovelpeerpharmacokinetics and pharmacodynamicspreventprimary endpointracial discriminationracial disparityreceptorrecruitreproductiveresponsesocial determinantssocial health determinantsunintended pregnancywomen of color
项目摘要
SUMMARY
The proposed project aims to increase our knowledge regarding the intersection of pharmacogenomics,
contraceptive efficacy, and health disparities. U.S. women of color are at much greater risk of experiencing
contraceptive failure, resulting in more unintended pregnancies than their white peers. While social
determinants of health, such as racial discrimination and access to healthcare, contribute meaningfully to
contraceptive availability and use, inherent pharmacogenomic differences could also account for significant
individual-to-individual disparities in efficacy. The most effective oral emergency contraceptive (EC) method,
ulipristal acetate (UPA), which works by blocking progesterone action in the preovulatory follicle, appears to be
less effective in certain populations even when optimally dosed. We have demonstrated that UPA is converted
to inactive metabolites by the enzyme cytochrome P450 3A5 (CYP3A5). Moreover, we established that the
primate ovarian follicle, the site of UPA action as an EC, expresses remarkably high levels of CYP3A5 through
the periovulatory interval and luteal development. The genotype and phenotype frequency of an active variant
of CYP3A5 is significantly greater in those identifying as Black as compared to whites, with the latter
possessing primarily a nonfunctional variant. Because active CYP3A5 is a major contributor to drug
metabolism, we hypothesize that UPA is significantly less effective at preventing ovulation in women with the
active CYP3A5 variant. In this proposal, we will determine if follicular CYP3A5 reduces intraovarian UPA levels
relative to what is observed systemically (Aim 1) using the clinically relevant rhesus macaque model. Studies
will also be performed to determine if blocking CYP3A5 activity leads to greater UPA efficacy in inhibiting
processes essential for ovulation. In complementary human subjects studies, we plan to assess if CYP3A5
genotype (active versus inactive form) determines UPA efficacy (Aim 2). Women recruited for this study will be
genotyped and categorized as possessing active or inactive CYP3A5 alleles and then assessed for UPA
pharmacodynamics. We will also explore other genetic variants that might play a role in drug metabolism. The
primary endpoint includes determining if significant differences exist in the rate at which UPA fails to prevent
ovulation and the pharmacokinetics of UPA metabolism related to the CYP3A5 genotype. The results of the
studies will determine if a genetic predisposition exists for racial disparities in contraceptive efficacy and the
risk for unintended pregnancy. The broad, long-term goal of this research includes providing a means to
maximize the therapeutic potential of UPA in women through testing to identify individuals at risk for failure
and/or developing approaches to limit drug metabolism.
总结
拟议的项目旨在增加我们对药物基因组学交叉点的了解,
避孕效果和健康差距。美国有色人种女性面临更大的风险
避孕失败,导致比白色同龄人更多的意外怀孕。而社会
健康的决定因素,如种族歧视和获得医疗保健的机会,
避孕的可用性和使用,固有的药物基因组学差异也可以解释显着
个体与个体之间的功效差异。最有效的口服紧急避孕药(EC)方法,
醋酸乌利司他(UPA)通过阻断排卵前卵泡中的孕酮作用而起作用,
即使在最佳剂量下,在某些人群中也不太有效。我们已经证明了UPA被转化为
通过酶细胞色素P450 3A 5(CYP 3A 5)转化为无活性代谢物。此外,我们确定,
灵长类动物的卵巢卵泡,UPA作为EC的作用部位,表达显著高水平的CYP 3A 5,
围排卵期和黄体发育。活性变异的基因型和表型频率
CYP 3A 5在黑人中显著高于白人,后者
主要具有非功能性变体。因为活性CYP 3A 5是药物的主要贡献者,
因此,我们假设UPA在阻止患有高脂血症的女性排卵方面的效果明显较差。
活性CYP 3A 5变体。在这个建议中,我们将确定卵泡CYP 3A 5是否降低卵巢内UPA水平
相对于使用临床相关的恒河猴模型全身观察到的(目的1)。研究
还将确定阻断CYP 3A 5活性是否会导致UPA抑制作用更大
排卵所必需的过程。在补充的人类受试者研究中,我们计划评估CYP 3A 5
基因型(活性与非活性形式)决定UPA的功效(目的2)。本研究招募的女性将
基因分型并分类为具有活性或非活性CYP 3A 5等位基因,然后评估UPA
药效学我们还将探索可能在药物代谢中发挥作用的其他遗传变异。的
主要终点包括确定UPA未能预防的比率是否存在显著差异。
排卵和UPA代谢的药代动力学与CYP 3A 5基因型有关。的结果
研究将确定在避孕效果方面是否存在种族差异的遗传倾向,
意外怀孕的风险。这项研究的广泛的长期目标包括提供一种手段,
通过测试确定有失败风险的个体,最大限度地发挥UPA在女性中的治疗潜力
和/或开发限制药物代谢的方法。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ALISON B EDELMAN其他文献
ALISON B EDELMAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ALISON B EDELMAN', 18)}}的其他基金
Disparities in emergency contraceptive metabolism dictate efficacy
紧急避孕药代谢的差异决定了功效
- 批准号:
10707384 - 财政年份:2022
- 资助金额:
$ 79.97万 - 项目类别:
Disparities in emergency contraceptive metabolism dictate efficacy
紧急避孕药代谢的差异决定了功效
- 批准号:
10834696 - 财政年份:2022
- 资助金额:
$ 79.97万 - 项目类别:
Improving emergency contraceptive effectiveness in obese women
提高肥胖女性紧急避孕药的有效性
- 批准号:
9975207 - 财政年份:2016
- 资助金额:
$ 79.97万 - 项目类别:
Determining the impact of COVID-19 vaccination on the menstrual cycle
确定 COVID-19 疫苗接种对月经周期的影响
- 批准号:
10429816 - 财政年份:2016
- 资助金额:
$ 79.97万 - 项目类别:
Improving Contraceptive Effectiveness in Obese Women
提高肥胖女性的避孕效果
- 批准号:
7937701 - 财政年份:2009
- 资助金额:
$ 79.97万 - 项目类别:
Improving Contraceptive Effectiveness in Obese Women
提高肥胖女性的避孕效果
- 批准号:
7696945 - 财政年份:2009
- 资助金额:
$ 79.97万 - 项目类别:
Contraceptive efficacy and body weight: Does obesity affect the risk of failure?
避孕效果和体重:肥胖是否会影响避孕失败的风险?
- 批准号:
7135687 - 财政年份:2006
- 资助金额:
$ 79.97万 - 项目类别:
相似海外基金
Linkage of HIV amino acid variants to protective host alleles at CHD1L and HLA class I loci in an African population
非洲人群中 HIV 氨基酸变异与 CHD1L 和 HLA I 类基因座的保护性宿主等位基因的关联
- 批准号:
502556 - 财政年份:2024
- 资助金额:
$ 79.97万 - 项目类别:
Olfactory Epithelium Responses to Human APOE Alleles
嗅觉上皮对人类 APOE 等位基因的反应
- 批准号:
10659303 - 财政年份:2023
- 资助金额:
$ 79.97万 - 项目类别:
Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization
深入分析跨等位基因、通路和疾病的 MHC I 类限制性肽呈递机制以及 TCR 发现/表征
- 批准号:
10674405 - 财政年份:2023
- 资助金额:
$ 79.97万 - 项目类别:
An off-the-shelf tumor cell vaccine with HLA-matching alleles for the personalized treatment of advanced solid tumors
具有 HLA 匹配等位基因的现成肿瘤细胞疫苗,用于晚期实体瘤的个性化治疗
- 批准号:
10758772 - 财政年份:2023
- 资助金额:
$ 79.97万 - 项目类别:
Identifying genetic variants that modify the effect size of ApoE alleles on late-onset Alzheimer's disease risk
识别改变 ApoE 等位基因对迟发性阿尔茨海默病风险影响大小的遗传变异
- 批准号:
10676499 - 财政年份:2023
- 资助金额:
$ 79.97万 - 项目类别:
New statistical approaches to mapping the functional impact of HLA alleles in multimodal complex disease datasets
绘制多模式复杂疾病数据集中 HLA 等位基因功能影响的新统计方法
- 批准号:
2748611 - 财政年份:2022
- 资助金额:
$ 79.97万 - 项目类别:
Studentship
Recessive lethal alleles linked to seed abortion and their effect on fruit development in blueberries
与种子败育相关的隐性致死等位基因及其对蓝莓果实发育的影响
- 批准号:
22K05630 - 财政年份:2022
- 资助金额:
$ 79.97万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genome and epigenome editing of induced pluripotent stem cells for investigating osteoarthritis risk alleles
诱导多能干细胞的基因组和表观基因组编辑用于研究骨关节炎风险等位基因
- 批准号:
10532032 - 财政年份:2022
- 资助金额:
$ 79.97万 - 项目类别:
Investigating the Effect of APOE Alleles on Neuro-Immunity of Human Brain Borders in Normal Aging and Alzheimer's Disease Using Single-Cell Multi-Omics and In Vitro Organoids
使用单细胞多组学和体外类器官研究 APOE 等位基因对正常衰老和阿尔茨海默病中人脑边界神经免疫的影响
- 批准号:
10525070 - 财政年份:2022
- 资助金额:
$ 79.97万 - 项目类别:
Leveraging the Evolutionary History to Improve Identification of Trait-Associated Alleles and Risk Stratification Models in Native Hawaiians
利用进化历史来改进夏威夷原住民性状相关等位基因的识别和风险分层模型
- 批准号:
10689017 - 财政年份:2022
- 资助金额:
$ 79.97万 - 项目类别: